CFDA approved the Registration Licenses of PIK3CA and BRAF Mutation Detection Kits from ACCB


    The Chinese Food and Drug Administration (CFDA) has approved the Registration Licenses of Human PIK3CA and BRAF gene mutation detection kits (fluorescent PCR) from Beijing ACCB Biotech Company Limited, and their license number is 2014 3401044 and 2014 3401045, respectively.
    Determination of PIK3CA and BRAF mutation detection kits is favor in clinical management of EGFR tyrosine kinase inhibitors and cetuximab in cancer patient target therapies, respectively. 

©Beijing ACCB Biotech Company Limited     All Rights Reserved Jing ICP Registration No05018742-1     Site map